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Introduction
Epstein–Barr virus (EBV) is a ubiquitous human γ-herpes
virus infecting more than 90% of the adult population
worldwide. EBV is associated with several malignancies
(e.g. Burkitt lymphoma, Hodgkin lymphoma and naso-
pharyngeal carcinoma) and thus has been classified as a
group 1 carcinogen [1]. Several studies have recently
hinted at a possible role for EBV in the pathogenesis of
breast carcinoma, which represents the most common
carcinoma of females in the Western world [2,3]. If sub-
stantiated, this would have potential implications for the
prevention and treatment of breast cancer. Immunothera-
peutic strategies based on EBV-specific cytotoxic T cells
are currently being developed for the treatment of EBV-
positive Hodgkin lymphoma and nasopharyngeal carci-
noma, and they could potentially also be applied to EBV-
associated breast carcinoma [4–6].
Against this background, the possibility that EBV may be
involved in the pathogenesis of breast carcinoma has
received great attention. The first studies addressing this
issue focused on medullary carcinomas since these are
morphologically similar to nasopharyngeal carcinoma.
However, these studies consistently failed to detect EBV
in medullary carcinomas using various techniques [7–9].
The possibility that invasive ductal and invasive lobular
breast carcinomas might be EBV-associated was raised
by Labrecque and coworkers [2], triggering a large
number of followup studies. However, the results and con-
clusions have been highly variable.
DTT = dithiothreitol; EBER = Epstein–Barr virus-encoded small RNA; EBNA1 = Epstein–Barr virus nuclear antigen 1; EBV = Epstein–Barr virus;
PCR = polymerase chain reaction; SSC = standard saline citrate.
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Abstract
Background: Epstein–Barr virus (EBV) is a ubiquitous human
γ-herpes virus infecting more than 90% of the population
worldwide. EBV is associated with certain malignancies (e.g.
Burkitt lymphoma, Hodgkin lymphoma and nasopharyngeal
carcinoma). Recent studies have raised the possibility that EBV
may also be involved in the pathogenesis of breast carcinoma,
the most common carcinoma of females. If substantiated, this
finding would have major implications regarding prevention and
therapy of the disease. The studies published so far have
employed diverse methods, however, and the results have
been controversial.
Methods: Using the EBV DNA PCR, EBV DNA in situ
hybridisation and in situ hybridisation for the detection of the
EBV-encoded RNAs, and using immunohistochemistry for the
demonstration of the EBV-encoded nuclear antigen 1, we have
studied a series of 59 invasive breast carcinomas for evidence
of EBV infection.
Results: EBV-encoded RNA-specific in situ hybridisation and
EBV-encoded nuclear antigen 1 immunohistochemistry were
negative in all cases. Using the PCR, EBV DNA was detected
in four out of 59 cases. These cases were further studied by
EBV DNA in situ hybridisation, showing an absence of viral
DNA from the tumour cells.
Conclusion: These results indicate that breast carcinoma is
not an EBV-associated tumour.
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It is generally accepted that EBV DNA can be detected in
up to 50% of breast carcinomas using the PCR
[2,3,10–13]. Results obtained with other methods are
more difficult to reconcile. Studies using immunohisto-
chemistry or in situ hybridisation have confirmed the pres-
ence of the virus only in a proportion of the PCR-positive
cases [2,3]. Moreover, EBV was detected only in a subset
of tumour cells in some reports, raising questions regard-
ing the possible role of the virus in breast carcinogenesis
[10–12]. Using in situ hybridisation, focal expression of
the small EBV-encoded RNAs (EBERs) was detected in
tumour cells of some breast carcinomas [11,12], while
other studies have demonstrated a complete absence of
EBER expression from breast carcinomas [14,15]. Since
the EBERs are expressed in all established EBV-associ-
ated tumours [1], the latter finding would appear to argue
against an association of EBV with breast carcinomas.
Nevertheless, expression of the EBV-encoded nuclear
antigen 1 (EBNA1) has been detected by immunohisto-
chemistry in a proportion of cases, and it has been argued
that an EBER-negative form of EBV infection may be
prevalent in breast carcinomas [3,11,16].
The evidence regarding a possible association of EBV with
breast carcinoma is thus controversial and, in view of the
high incidence of this tumour, requires clarification. Before
undertaking a study of breast carcinoma, we felt it was
important to establish criteria for the definition of EBV-asso-
ciated tumours. The study of DNA extracts by PCR is clearly
not satisfactory since it leaves unanswered the question of
the cellular source of any viral genomes detected. This con-
sideration also applies to Southern blot hybridisation,
although determination of viral clonality is possible with this
method, thus allowing conclusions regarding the clonality of
the cell population harbouring the virus [17].
Unequivocal localisation of the virus is best achieved by
in situ techniques. Immunohistochemical methods are
available for the detection of viral proteins in paraffin sec-
tions. However, some of these are not consistently
expressed in latent EBV infection [1]. Only EBNA1 is
expressed in all known forms of viral latency, yet the anti-
bodies available for the detection of this protein usually
produce only weak staining. A lack of detectable EBNA1
expression thus cannot be taken as proof of absence of
the virus [18,19]. In recent years, in situ hybridisation for
the detection of the EBERs has become the ‘gold stan-
dard’ for the detection of the virus because of its high sen-
sitivity owing to the highly abundant expression of these
molecules [1]. The application of this method is based on
the assumption that the EBERs are consistently expressed
in EBV infection. Recent studies of hepatocellular carci-
noma have raised the possibility of an EBER-negative form
of viral infection [20]. DNA in situ hybridisation can be
used for the localisation of the viral genome [7]. However,
this method is prone to false-negative results due to the
usually low copy number of the viral genome in latently
infected cells.
Based on these considerations, we decided to carry out a
study of breast carcinomas employing a combination of
methods. All cases were screened for the presence of
EBV by EBER in situ hybridisation, by EBNA1 immuno-
staining and by EBV DNA PCR. Cases positive for viral




Formalin-fixed, paraffin-embedded tissue blocks from
59 invasive breast carcinomas were retrieved from the
files of the Institute for Pathology, Friedrich-Alexander
University, Erlangen, Germany. These included 30 invasive
ductal carcinomas, 26 invasive lobular carcinomas, two
medullary carcinomas and one undifferentiated carcinoma.
Among these 59 carcinomas, 50 cases were classified as
grade 2, seven cases as grade 3 and two cases were
identified as grade 1. The age of the patients ranged from
30 to 89 years, and all patients were female.
For control, paraffin sections from EBV-positive, undiffer-
entiated nasopharyngeal carcinomas were used.
Plasmids, probes, and in situ hybridisation
The plasmids harbouring inserts specific for the small
EBV-encoded nuclear RNAs (EBER1 and EBER2) have
been described previously [21]. Single-stranded anti-
sense and sense RNA probes were obtained from these
plasmids by in vitro transcription in the presence of
35S-labelled UTP [22]. EBER in situ hybridisation was
carried out as described in detail elsewhere [22]. In
brief, paraffin sections were dewaxed and rehydrated
through graded ethanols, treated with 0.2 N HCl for
20 min, digested with 0.5 mg/ml pronase (Boehringer,
Mannheim, Germany) for 10 min, fixed in cold 4%
paraformaldehyde for 20 min, and acetylated using a
freshly prepared 1 : 400 solution of acetic anhydride in
0.1 M triethanolamine (pH 8.0) for 10 min. Sections were
then dehydrated through graded ethanols and air dried.
Approximately 50 µl hybridisation mixture (50%
deionised formamide/10% dextran sulfate/2 × standard
saline citrate [SSC]/0.2 mg/ml yeast tRNA/10 mM dithio-
threitol [DTT]), including 1 × 105 cpm labelled probe,
were applied to each section. After hybridisation
overnight at 50°C, sections were washed in 50% for-
mamide/1 × SSC/10 mM DTT at 52°C for 4 hours. To
remove nonspecifically bound probe, sections were sub-
jected to RNase A digestion (Sigma, Steinheim,
Germany; 20 µg/ml, 30 min, 37°C). Sections were then
rinsed in 2 × SSC and 0.1 × SSC, dehydrated through
graded ethanols and dipped into Ilford G5 emulsion
(Ilford, Mobberley, Cheshire, UK).
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For the detection of EBV DNA, a plasmid harbouring the
BamHI W internal repetitive fragment of the EBV genome
was used [7]. Total plasmid DNA was labelled with
35S-dCTP by nick translation using a commercially avail-
able kit (Amersham Pharmacia Biotech, Freiburg,
Germany). Following the nick translation reaction, labelled
DNA was separated from unincorporated nucleotides
using Sephadex columns (Nick columns; Amersham Phar-
macia Biotech) according to the supplier’s instructions.
Prehybridisation treatment was essentially the same as for
RNA in situ hybridisation, with minor modifications as
described previously [7]. Approximately 50 µl hybridisation
mixture (50% deionised formamide/10% dextran
sulfate/2 × SSC/ 30 µg/ml herring sperm DNA/10 mM
DTT) containing 40–50 ng/ml labelled probe were added
per slide. Sections were covered with siliconised cover-
slips. Probe and cellular DNA were denatured by placing
slides onto a 90°C heat block for 3 min. Hybridisation was
carried out overnight at 37°C in an atmosphere of 50%
formamide. Slides were washed in 50% formamide/
0.1 × SSC/10 mM DTT at 37°C for 4 hours, followed by
2 × SSC/10 mM DTT and 0.1 × SSC/10 mM DTT, both for
30 min at room temperature. Sections were dehydrated
through graded ethanols, air dried and dipped as already
described. For the detection of EBERs and EBV DNA,
sections were exposed at 4°C for 3–12 days.
EBNA-1 immunohistochemistry
Paraffin sections were dewaxed in xylene for 30 min at
room temperature and rehydrated through graded
ethanols (5 min each in 100%, 96% and 70% ethanol and
water). The EBNA1-specific rat monoclonal antibodies,
1H4 and 2B4, were kindly provided by Elisabeth
Kremmer, Munich [18]. Bound primary antibodies were
detected using a biotinylated rabbit antiserum specific for
rat immunoglobulins, streptavidin biotinylated peroxidase
complex ABC–PO and a tyramide signal amplification pro-
tocol followed by detection of precipitated biotin using
alkaline phosphatase-labelled ABC (all Dako, Hamburg,
Germany). Fast Red (Sigma, Steinheim, Germany) served
as a chromogen.
EBV DNA PCR
For PCR, one 10 µm paraffin section from each case was
dewaxed in xylene for 30 min at room temperature, rehy-
drated through graded ethanols (5 min each in 100%,
96% and 70% ethanol) and air dried. Tissues were incu-
bated in 200 µl buffer (50 mM KCl, 10 mM Tris–HCl
[pH 8.3], 2.5 mM MgCl, 0.1 mg/ml gelatine, 0.45% NP-40,
0.45% Tween-20) and 0.2 mg/ml proteinase K overnight
at 56°C, followed by heat inactivation of proteinase K.
Five microlitre aliquots of DNA extracts were subjected to
PCR: 5 min denaturation at 94°C, 10 cycles of 20 s at
94°C, 20 s at 58.3°C and 30 s at 72°C, followed by
25 cycles of 20 s at 94°C, 20 s at 53.3°C and 30 s at
72°C, completed by 150 s at 72°C. The reaction volume
was 50 µl containing 5 µl DNA, 1 × polymerase buffer,
1.5 mM MgCl, 200 µM dNTP, 1 U Taq-polymerase and
400 nM primer mix (5′-CAC TTT AGA GCT CTG GAG
GA-3′ and 5′-TAA AGA TAG CAG CAG CAC AG-3′).
The primers resulted in the amplification of a 153 base
pair fragment of the EBV BamHI W internal repetitive frag-
ment. For control, a 303 base pair fragment of the β-globin
gene was amplified using published primers. The PCR
products were analysed by electrophoresis using 2%
agarose gels.
Results
Lack of EBER and EBNA1 expression in breast
carcinomas
All cases were first subjected to in situ hybridisation for
the detection of EBER expression using 35S-labelled
probes. In breast carcinomas, rare EBV-infected lympho-
cytes were detected in the stroma of one case (Fig. 1a).
However, there was no detectable EBER expression in the
tumour cells in any of the 59 cases (Fig. 1a). By contrast,
expression of the EBERs was readily detectable in tumour
cells of undifferentiated nasopharyngeal carcinomas
(Fig. 1b). All cases were then examined for EBNA1 expres-
sion by immunohistochemistry using two previously
described rat monoclonal antibodies, 1H4 and 2B4
[18,19]. Again, nuclear staining typical of EBNA1 expres-
sion was not observed in any of the breast carcinoma
cases (Fig. 1c). EBNA1 expression was detected in
nasopharyngeal carcinoma control sections using this
approach (Fig. 1d).
EBV DNA in breast carcinomas
The possibility of an EBER-negative form of latent EBV
infection has recently been suggested [20]. Also, immuno-
histochemical detection of EBNA1 is not very reliable and
the absence of a specific staining does not definitely
exclude the possibility of EBNA1 expression. For these
reasons, experiments were carried out aimed at the detec-
tion of the viral genome. First, DNA extracts from paraffin
sections of all cases were subjected to PCR using primers
specific for the BamHI W fragment of the EBV genome.
After 35 amplification cycles, a PCR product of the
expected size was observed in four of 59 cases (6.8%;
data not shown). Subsequent analysis of the EBV DNA
PCR-positive cases by EBV DNA in situ hybridisation
using a 35S-labelled probe specific for the EBV BamHI W
fragment yielded negative results (Fig. 1e), while the same
approach led to a strong labelling of nasopharyngeal car-
cinoma cell nuclei (Fig. 1f).
Discussion
In keeping with previous reports, we show that EBV DNA
can be detected in a proportion of breast carcinoma
samples by PCR [2,3,12,13]. The significance of this
finding crucially depends on the localisation of the virus
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and, in this respect, published evidence is controversial.
Using a highly sensitive in situ hybridisation method, we
show that the EBERs are not expressed in breast carci-
noma tumour cells while EBV-infected lymphocytes were
occasionally detected in the tumour stroma. This is in
agreement with recent EBER in situ hybridisation studies
of breast carcinomas [14,15].
Expression of the EBERs has been detected in all known
virus-associated tumours and has become the standard
method for the detection of EBV infection. However, the
possibility of an EBER-negative form of EBV infection has
recently been raised [3,20]. To address this problem, we
have looked for the expression of another viral gene
product, EBNA1. The presence of EBNA1 in EBV-
infected cells is required for the maintenance of the EBV
episome, and thus EBNA1 should be expressed in all pro-
liferating EBV-infected cells [23]. Indeed, using immuno-
histochemistry, EBNA1 has been detected in EBV-
associated nasopharyngeal and gastric carcinomas [19].
However, there was clearly no EBNA1 expression
detectable in our breast carcinoma cases, while appropri-
ate controls were positive. This is in marked contrast to
other studies using a similar approach [3,16]. The differ-
ence between the present study and these other reports
is likely to be due to technical reasons. Most importantly, it
has been demonstrated previously that one of the EBNA1-
specific antibodies used in the present study and in other
studies, clone 2B4, is prone to produce nonspecific
nuclear labelling of EBV-negative cells [19].
The detection of both EBERs and EBNA1 rests on the
active expression of the viral genome. Since it is conceiv-
able that the viral genome may be present in an entirely
silent form, we have also examined our cases for the pres-
ence of viral DNA. By PCR, we show that only a small pro-
portion of breast carcinoma samples carry detectable EBV
DNA. In situ hybridisation analysis of these cases showed
that the tumour cells in these cases were EBV-negative. In
agreement with a previous study, the present results
suggest that EBV DNA detected by PCR in breast carci-
noma tissues is likely to relate to the presence of EBV-
infected lymphocytes in the tumour stroma and does not
indicate infection of the tumour cells with the virus [13].
These results provide no evidence for an involvement of
EBV in the pathogenesis of breast carcinomas occurring
in German patients. We have previously demonstrated
that squamous cell nasopharyngeal carcinomas are regu-
larly associated with EBV in Hong Kong, while only
approximately 30% of cases from Europe and central
China are EBV-positive [24]. Theoretically, the possibility
thus remains that breast carcinomas may be associated
with EBV in other geographical areas.
Conclusion
The present results strongly argue against a direct role for
EBV in the pathogenesis of breast carcinoma. Breast carci-
nomas should not be regarded as EBV-associated tumours.
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